Covaxin demonstrates 100% efficacy against severe COVID-19, overall interim clinical efficacy at 78%
Hyderabad: Leading vaccine maker Bharat Biotech and the Indian Council of Medical Research (ICMR) have announced interim results from phase 3 clinical trials of Covaxin, which show 78 per cent overall clinical efficacy and 100 per cent efficacy against severe COVID-19. The second interim analysis...











































